Join the Daxxify group to help and get support from people like you.
Daxxify News
FDA Approves First Therapeutic Indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 Approval expands the Daxxify® label to include efficacy data over the 52-week ASPEN repeat dose clinical study. ...
FDA Approves Daxxify (daxibotulinumtoxinA-lanm) for Temporary Improvement of Moderate to Severe Glabellar Lines (Frown Lines)
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sep. 8, 2022-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that...
Ask a question
To post your own question to this support group, sign in or create an account.